Addex Therapeutics Ltd (ADXN.SW)
- Previous Close
0.1595 - Open
0.1600 - Bid 0.1525 x --
- Ask --
- Day's Range
0.1445 - 0.1645 - 52 Week Range
0.0362 - 0.2600 - Volume
894,095 - Avg. Volume
1,063,310 - Market Cap (intraday)
19.136M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1500 - Earnings Date Apr 18, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for pain, anxiety, and addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.
www.addextherapeutics.comRecent News: ADXN.SW
Performance Overview: ADXN.SW
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ADXN.SW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ADXN.SW
Valuation Measures
Market Cap
20.28M
Enterprise Value
15.85M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.21
Price/Book (mrq)
5.14
Enterprise Value/Revenue
9.83
Enterprise Value/EBITDA
-1.55
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-99.44%
Return on Equity (ttm)
-348.48%
Revenue (ttm)
1.65M
Net Income Avi to Common (ttm)
-10.56M
Diluted EPS (ttm)
-0.1500
Balance Sheet and Cash Flow
Total Cash (mrq)
3.87M
Total Debt/Equity (mrq)
30.06%
Levered Free Cash Flow (ttm)
-6.21M